Skin imaging study for diffuse scleroderma patients
Part of Skin clinical trials.
This study uses a special camera (SFDI) to take painless images of your skin to see how scleroderma affects it. You may also be asked for a small skin sample (biopsy) to help understand the condition better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with scleroderma within the last 5 years and have diffuse skin involvement
- Or diagnosed with scleroderma within the last 3 years and have RNA Polymerase III or anti-topoisomerase antibodies
- No skin cancer in the last 2 years (excluding minor skin cancers that were treated)
- No wounds or rashes on the skin areas to be tested
- No other serious illness that would make life expectancy less than 5 years
- Healthy volunteers must not have any autoimmune disease or known skin problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at families where two first-degree relatives have systemic scleroderma, a rare autoimmune disease that affects the skin and organs. It aims to understand genetic and environmental factors by examining patients and their family members.
This study compares skin samples from people with scleroderma and healthy volunteers to understand what goes wrong in the skin. It may help researchers find new treatment targets.
This study uses a detailed look at your skin and scalp (often with a magnifying exam) to learn more about systemic scleroderma. It may help doctors understand the condition better and improve how it’s assessed over time.
This trial collects skin samples from people with scleroderma and from healthy volunteers undergoing plastic surgery. Researchers will study the genes in skin cells to better understand the disease.
This study uses skin samples from people with scleroderma, their relatives, and healthy volunteers to create stem cells in a lab. The goal is to learn more about the disease and find better ways to treat it.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
Hear when a new Systemic Scleroderma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.